Loading
Allterum Therapeutics makes an antibody against CD127, part of a growth signal receptor found on some leukaemia cells. It is being tested in people with acute lymphoblastic leukaemia or lymphoblastic lymphoma that has come back or not responded.
Allterum Therapeutics, a Houston, Texas company in the Fannin portfolio, develops 4A10, a human IgG1 monoclonal antibody against CD127 (the interleukin-7 receptor alpha chain), which the company says both blocks growth signalling and recruits immune killing. The antibody was developed at the US National Cancer Institute and licensed exclusively to Fannin, which assigned the licence to Allterum. The first-in-human phase 1 trial ALT-101 (NCT07586618) tests weekly intravenous 4A10 in relapsed or refractory acute lymphoblastic leukaemia and lymphoblastic lymphoma, with the National Cancer Institute and the Cancer Prevention Research Institute of Texas listed as collaborators. The company also describes preclinical work in other CD127-expressing lymphomas and solid tumours and an interest in inflammatory disease. Its first registered cancer trial, NCT07586618, was posted on ClinicalTrials.gov in May 2026.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/